Liraglutide (Saxenda)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Obesity

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
EU
  • Saxenda: weight management in adults with obesity or overweight with comorbidity; later extended to children
Product first approved 2015EMA
CA
  • SAXENDA® (liraglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obesity), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention. Limitation of Use: 1. Clinical efficacy and safety data from patients with BMI 27 to 29.9 kg/m2 in the presence of at least one...
Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (21)
Obesity
NCT04775082 · Novo Nordisk A/S
2021-03-04 – 2027-02-08 · Obesity
What this study did
NCT05952882 · Mỹ Đức Hospital
2023-11-01 – 2025-12-31 · Polycystic Ovary Syndrome, Obesity, Infertility, Female
What this study did
NCT05965908 · Beni-Suef University
2024-08-01 – 2025-12-30 · Polycystic Ovary
What this study did
NCT03115424 · Mayo Clinic
2017-06-22 – 2024-05-30 · Obesity
What this study did
NCT04605861 · Shanghai Zhongshan Hospital
2020-08-18 – 2023-04-15 · Obese, Overweight
What this study did
NCT03671733 · Xiangya Hospital of Central South University
2018-09-01 – 2022-09-01 · Obesity
What this study did
NCT04487743 · Xiangya Hospital of Central South University
2020-05-09 – 2022-06 · Obesity
What this study did
NCT04525300 · Xiangya Hospital of Central South University
2020-05-24 – 2022-06 · Obesity
What this study did
NCT03374956 · Mayo Clinic
2017-12-11 – 2022-05-26 · Obesity
What this study did
NCT03480022 · Woman's
2018-09-26 – 2021-05-19 · Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
What this study did
NCT02527200 · Novo Nordisk A/S
2015-11-09 – 2020-11-19 · Metabolism and Nutrition Disorder, Obesity
What this study did
NCT04325581 · Post Graduate Institute of Medical Education and Research, Chandigarh
2016-08-01 – 2018-12-31 · Weight Loss
What this study did
NCT02963922 · Novo Nordisk A/S
2017-02-06 – 2018-09-25 · Metabolism and Nutrition Disorder, Obesity
What this study did
NCT02963935 · Novo Nordisk A/S
2017-02-06 – 2018-06-19 · Metabolism and Nutrition Disorder, Obesity
What this study did
NCT02417103 · Universitätsklinikum Hamburg-Eppendorf
2011-12 – 2016-12 · Obesity
What this study did
NCT01784965 · Stanford University
2009-12 – 2012-12 · Pre-diabetes, Older Adults
What this study did
Phase 2/3 (1)
Obesity
NCT04683237 · Xiaojun Chen
2021-03-20 – 2026-11-30 · Atypical Endometrial Hyperplasia, Obese, Fertility Issues
What this study did
Phase 2 (8)
Obesity
NCT04883346 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2021-06-21 – 2024-04-30 · Obesity, Status Post Sleeve Gastrectomy
What this study did
NCT04529278 · Fondation Hôpital Saint-Joseph
2021-01-18 – 2023-12-31 · Diabetes Mellitus, Type 2, Hemodialysis, Obese
What this study did
NCT03158805 · Lindner Center of HOPE
2017-04-26 – 2023-01-01 · Bipolar Disorder, Obesity
What this study did
NCT04839237 · Xiangya Hospital of Central South University
2017-12-01 – 2021-12-01 · Obesity
What this study did
NCT03523273 · Michael Camilleri, MD
2017-11-29 – 2021-08-31 · Obesity
What this study did
NCT02082496 · University of Copenhagen
2014-06 – 2019-04 · Obesity
What this study did
NCT02647944 · Mayo Clinic
2015-12-18 – 2016-12-30 · Obesity
What this study did
NCT00422058 · Novo Nordisk A/S
2007-01-10 – 2009-04-30 · Metabolism and Nutrition Disorder, Obesity
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01832532 · Children's Hospital Medical Center, Cincinnati
2013-04 – 2015-12 · Sleep Apnea, Sleep Disordered Breathing
What this study did
Phase 1 (14)
Obesity
NCT06171152 · University of Chicago
2024-01-26 – 2027-10-01 · Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
What this study did
NCT06217848 · Seoul National University Hospital
2022-11-28 – 2024-03-08 · Panhypopituitarism, Craniopharyngioma, Hypothalamic Obesity
What this study did
NCT03500484 · Yale University
2018-06-06 – 2020-06-25 · Obesity, Childhood, Neural Development
What this study did
NCT03757130 · Amgen
2018-11-26 – 2019-12-16 · Obesity
What this study did
NCT03041792 · Pfizer
2017-02-20 – 2018-01-16 · Obesity
What this study did
NCT02870231 · Novo Nordisk A/S
2016-08-18 – 2017-09-03 · Metabolism and Nutrition Disorder, Obesity
What this study did
NCT02696148 · Novo Nordisk A/S
2016-03-14 – 2017-04-13 · Metabolism and Nutrition Disorder, Obesity
What this study did
NCT02717858 · Novo Nordisk A/S
2016-03-16 – 2017-02-27 · Metabolism and Nutrition Disorder, Obesity
What this study did
NCT02235961 · Novo Nordisk A/S
2014-09-04 – 2016-07-06 · Metabolism and Nutrition Disorder, Obesity
What this study did
NCT02207348 · Novo Nordisk A/S
2014-08 – 2014-09 · Metabolism and Nutrition Disorder, Obesity
What this study did
NCT01789086 · Novo Nordisk A/S
2013-02 – 2014-05 · Metabolism and Nutrition Disorder, Obesity
What this study did
NCT00978393 · Novo Nordisk A/S
2009-09-16 – 2011-06-08 · Metabolism and Nutrition Disorder, Obesity
What this study did
Phase 4 (39)
Obesity
NCT06742710 · Peking University Third Hospital
2025-05-22 – 2029-12-31 · PCOS, Obesity, Infertility
What this study did
NCT07590219 · University of Sao Paulo General Hospital
2024-03-30 – 2028-04 · Severe Obesity, Cardiovascular Function, Liraglutide, Childhood Obesity, Echocardiography, Speckle Tracking
What this study did
NCT06865365 · Medical University of Vienna
2025-05-01 – 2028-02-01 · Obesity, Adolescent
What this study did
NCT07301437 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2026-05-01 – 2027-08-31 · Overweight and Obese Adults
What this study did
NCT02944500 · Beth Israel Deaconess Medical Center
2016-11 – 2027-06 · Obesity
What this study did
NCT07913685 · Medical University of Bialystok
2023-04-05 – 2026-01-19 · Obesity & Overweight
What this study did
NCT07374445 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2023-09-01 – 2025-06-01 · Obesity, Weight Loss, Bariatric Surgery
What this study did
NCT06438146 · Brigham and Women's Hospital
2024-05-02 – 2025-05 · Obesity, HIV Infections
What this study did
NCT06501326 · Affiliated Hospital of Nantong University
2023-11-01 – 2025-02-28 · Non-alcoholic Fatty Liver Disease, Obesity
What this study did
NCT04531176 · The Cleveland Clinic
2020-09-01 – 2023-08-04 · Type 2 Diabetes, Obesity
What this study did
NCT04575194 · National and Kapodistrian University of Athens
2020-09-08 – 2023-05-30 · Obesity, Blood Pressure
What this study did
NCT06201819 · Hospital Civil Juan I. Menchaca
2022-12-18 – 2023-05-01 · Weight Loss, Bariatric Surgery Candidate, Obesity, Morbid
What this study did
NCT04781998 · Anders Fink-Jensen, MD, DMSci
2021-07-01 – 2022-09-01 · Mental Disorder, Metabolic Disturbance, Feasibility, Overweight and Obesity, Liraglutide
What this study did
NCT03036800 · University of Leicester
2017-11-28 – 2022-02-25 · Obesity, Weight Loss, Diabetes Mellitus
What this study did
NCT02920190 · University of Miami
2020-09-01 – 2021-12-31 · Monoclonal Gammopathies, Overweight, Obesity
What this study did
NCT04122716 · Signe Torekov
2016-09 – 2021-11 · Obesity
What this study did
NCT04008290 · Universitaire Ziekenhuizen KU Leuven
2020-04-01 – 2021-04-01 · Obesity
What this study did
NCT03048578 · NYU Langone Health
2017-05-22 – 2021-03-02 · Obesity
What this study did
NCT03038620 · University of Texas Southwestern Medical Center
2017-01 – 2020-10-13 · Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
What this study did
NCT03642600 · Universitaire Ziekenhuizen KU Leuven
2019-02-28 – 2020-07-03 · PCOS, Obesity, Metabolic Syndrome
What this study did
NCT03341429 · University College, London
2018-08-22 – 2020-06-11 · Obesity
What this study did
NCT04046822 · Federico II University
2019-01-09 – 2020-04-30 · Obesity, Weight Loss, Microbiome
What this study did
NCT03347890 · Zoltan Pataky
2018-03-05 – 2020-03-30 · Obesity
What this study did
NCT02928679 · Henrik Gudbergsen
2016-11 – 2019-03-20 · Osteoarthritis, Obesity
What this study did
NCT02931383 · Henrik Gudbergsen
2016-11 – 2019-03 · Osteoarthritis, Obesity
What this study did
NCT02905864 · Henrik Gudbergsen
2016-11 – 2019-03 · Osteoarthritis, Obesity
What this study did
NCT02910570 · Parker Research Institute
2016-11 – 2019-03 · Osteoarthritis, Knee
What this study did
NCT02928614 · Henrik Gudbergsen
2016-11 – 2019-03 · Osteoarthritis, Obesity
What this study did
NCT02911818 · University of Pennsylvania
2016-09 – 2018-12 · Obesity
What this study did
NCT02616003 · Sana Klinikum Offenbach
2014-04 – 2018-04 · Morbid Obesity, Bariatric Surgery Candidate
What this study did
NCT03034941 · University Medical Centre Ljubljana
2014-04 – 2016-12 · Obesity, PCOS
What this study did
NCT03353948 · University Medical Centre Ljubljana
2014-09-01 – 2016-09-01 · Polycystic Ovary Syndrome, Obesity, Infertility, Female
What this study did
NCT02909933 · University Medical Centre Ljubljana
2015-07 – 2015-10 · Polycystic Ovary Syndrome, Obesity
What this study did
NCT03619330 · University Medical Centre Ljubljana
2014-12 – 2015-08 · Hypogonadism, Obesity
What this study did
NCT01739049 · Universiti Kebangsaan Malaysia Medical Centre
2012-11 – 2015-01 · Binge Eating Behaviour
What this study did
NCT02187250 · University Medical Centre Ljubljana
2014-03 – 2014-06 · PCOS, Obesity
What this study did
NCT01562678 · Beth Israel Deaconess Medical Center
2012-03 – 2014-05 · Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss, Hunger
What this study did
NCT01911468 · University Medical Centre Ljubljana
2011-11 – 2013-04 · PCOS, Obesity
What this study did
NCT01899430 · University Medical Centre Ljubljana
2011-11 – 2013-04 · PCOS, Obesity
What this study did
Early phase / not applicable (9)
Obesity
NCT05705388 · Emirates Health Services (EHS)
2023-01-16 – 2026-01-03 · Obesity
What this study did
NCT05779644 · RenJi Hospital
2023-02-23 – 2025-02-23 · Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat, Non-Alcoholic Fatty Liver Disease, Metabolism Disorder, Glucose, Metabolism Disorder, Lipid
What this study did
NCT05268627 · Mansoura University
2022-01-27 – 2023-01-27 · Obesity
What this study did
NCT05285397 · General Committee of Teaching Hospitals and Institutes, Egypt
2022-03-10 – 2022-09 · Morbid Obesity
What this study did
NCT03795701 · Texas Tech University
2019-01-08 – 2022-05-01 · Obesity
What this study did
NCT04643301 · Zuyderland Medisch Centrum
2020-12-21 – 2021-12-31 · Obesity, Obesity, Morbid
What this study did
NCT03520062 · Nicolai Jacob Wewer Albrechtsen
2017-08-15 – 2020-01-01 · Obesity
What this study did
NCT03534310 · Catholic University of the Sacred Heart
2015-11-02 – 2017-04-10 · Obesity
What this study did
Other / comorbidity
NCT04186494 · St Vincent's University Hospital, Ireland
2019-12-02 – 2022-07-31 · Sleep Apnea, Obstructive
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Obesity
NCT03986008 · Xiangya Hospital of Central South University
2019-12-01 – 2021-12-23 · Obesity
What this study did
NCT04074161 · Novo Nordisk A/S
2019-09-11 – 2021-05-11 · Overweight, Obesity
What this study did
NCT02654665 · Changi General Hospital
2014-03 – 2018-12 · Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss, Non-alcoholic Steatohepatitis (NASH)
What this study did
Phase 2 (4)
Obesity
NCT05111912 · Sciwind Biosciences APAC CO Pty. Ltd.
2021-11-30 – 2022-12-20 · Obesity
What this study did
NCT03856047 · Novo Nordisk A/S
2019-03-01 – 2021-03-25 · Overweight, Obesity
What this study did
NCT03486392 · Janssen Research & Development, LLC
2018-03-26 – 2019-03-08 · Obesity
What this study did
NCT02453711 · Novo Nordisk A/S
2015-10-01 – 2017-04-12 · Metabolism and Nutrition Disorder, Obesity
What this study did
Phase 1 (1)
Obesity
NCT04311411 · Eli Lilly and Company
2020-08-24 – 2022-12-16 · Obesity, Overweight
What this study did
Phase 4 (1)
Obesity
NCT05579249 · Novo Nordisk A/S
2023-01-19 – 2024-11-27 · Obesity
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Obesity
NCT06836284 · Karolinska Institutet
2026-02-13 – 2027-05-01 · Childhood Obesity, Treatment Adherence
What this study did

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Obesity: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Liraglutide (Saxenda): this drugApprovedPeptideGLP-1 receptorReliable signal
NCT02918279: Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54)
NCT01557166: Change From Baseline in Apnoea-hypopnoea Index (AHI) (Week 0, Week 32): Liraglutide 3.0 mg -12.22 events/hour (Standard Deviation 23.34) vs Placebo -6.08 events/hour (Standard Deviation 25.9)
Dulaglutide (Trulicity)
Approved(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Liraglutide (Victoza)
Approved(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Lixisenatide (Adlyxin / Lyxumia)
Approved(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Naltrexone / Bupropion (Contrave)ApprovedSmall moleculeOpioid receptor / dopamine (combination), Dopamine/norepinephrine transporternot yet graded
NCT03374956: Change in Total Body Weight (baseline to 12 weeks): Intervention Group -7.7% (IQR -11 to -4.7) vs Control Group -6.5% (IQR -11 to -2.3) phase 3 result · pivotal pending
Orforglipron (Foundayo)ApprovedSmall moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
Orlistat (Xenical)ApprovedSmall moleculePancreatic/gastric lipaseWeak signalNo reviewed efficacy summary in this indication
Phentermine / Topiramate (Qsymia)ApprovedSmall moleculeNoradrenergic/anticonvulsant (combination)Reliable signal
NCT00553787: Percent Weight Loss From Baseline to Week 56 (Baseline to 56 weeks): VI-0521 Mid 7.81% (Standard Error 0.365) | VI-0521 Top 9.84% (Standard Error 0.275) vs Placebo 1.24% (Standard Error 0.277)
NCT00554216: Percent Weight Loss From Baseline to Week 56 (baseline to 56 weeks): VI-0521 Low 5.1% (Standard Error 0.538) | VI-0521 Top 10.92% (Standard Error 0.392) vs Placebo 1.55% (Standard Error 0.395)
Semaglutide (Ozempic)
Approved(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Semaglutide (Rybelsus)
Approved(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (Wegovy Tablets)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
NCT03548935: Change in Body Weight (%) (Baseline (week 0) to week 68): Semaglutide 2.4 mg — In-trial observation period: -15.6% (Standard Deviation 10.1); On-treatment observation period: -16.9% (Standard Deviation 9.4) vs Placebo — In-trial observation period: -2.8% (Standard Deviation 6.5); On-treatment observation period: -3.1% (Standard Deviation 6.4)
Setmelanotide (Imcivree)ApprovedPeptideMC4RWeak signal
NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984)
NCT03287960: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52): Setmelanotide (Entire Study) 45.5% (95% CI 19.96 to 72.88)
Tirzepatide (Zepbound)ApprovedPeptideGLP-1/GIP receptor (dual)Reliable signal
NCT05412004: Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21)
NCT04660643: Percent Change From Randomization in Body Weight at Week 88 (Randomization (Week 36), Week 88): Tirzepatide MTD -6.7 percent change (Standard Error 0.52) vs Placebo 14.8 percent change (Standard Error 0.53)
Albenatide
Phase 3(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorPartial signal
NCT06703021: Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001)
ASC30Phase 3Small moleculeGLP-1 receptorPartial signal
NCT07002905: Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06712836: Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results).
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06973681: Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity)
BofanglutidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT03856047: Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2)
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT05813925: Change in body weight at week 68: -18.4% (SE 0.7) CagriSema vs -11.9% (SE 0.7) semaglutide alone; ETD -6.5 percentage points (95% CI -8.4 to -4.6; p<0.0001)
DA-302168SPhase 3Small moleculeGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EcnoglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT05813795: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met.
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT05997576: Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025).
EfpeglenatidePhase 3PeptideGLP-1 receptorReliable signal
NCT06174779: Percent change in body weight from baseline at Week 40: -9.75% (efpeglenatide/HM11260C) vs -0.95% (placebo); least-squares mean difference -8.13 percentage points, statistically significant
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signalNo reviewed efficacy summary in this indication
EloralintidePhase 3PeptideAmylin receptorReliable signal
NCT06230523: Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%.
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)Reliable signal
NCT06525935: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001)
Exendin-4 Fc Fusion (JY09)
Phase 3(overall)
Protein / enzyme therapeuticGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
HDG1901
Phase 3(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
IcoSema (Kyinsu)
Phase 3(overall)
PeptideInsulin receptor (basal), GLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
LenbelintidePhase 3PeptideAmylin receptorPartial signalNo reviewed efficacy summary in this indication
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signal
NCT05669599: Primary endpoint percent change in body weight baseline to week 52 (treatment policy estimand): -12.3% to -16.2% across doses vs -2.5% placebo (obesity cohort); -8.4% to -12.3% vs -1.7% placebo (obesity-diabetes cohort)
MazdutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT05607680: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met.
MDR-001Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
MibavademabPhase 3Monoclonal antibodyLeptin receptorPartial signalNo reviewed efficacy summary in this indication
Noiiglutide
Phase 3(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
OlatorepatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06839664: Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo.
Pegloxenatide (Fulaimei)
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
PetrelintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signal
NCT06662539: Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05).
RAY1225Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT05931367: Co-primary 1, WOMAC pain subscale change to week 68 (treatment-regimen estimand): retatrutide 9 mg -4.0 points (-67.2%), 12 mg -3.7 points (-62.6%) vs placebo -2.1 points (-35.1%); statistically significant for each dose per the sponsor (p not printed), met. Co-primary 2, percent change in body weight to week 68: 9 mg -20.0%, 12 mg -23.7% vs placebo -4.6%; statistically significant for each dose per the sponsor (p not printed), met.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06396429: Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorReliable signal
NCT06904105: Percent body-weight change at week 44, treatment-policy estimand (prespecified primary): -8.0% (120 mg) and -9.8% (180 mg) vs -2.4% placebo, superiority stated as met (no p-value given). Proportion with at least 5% weight loss at week 44 (registry primary): 58.6% (120 mg) and 68.2% (180 mg); placebo rate and significance not reported.
SurvodutidePhase 3PeptideGLP-1/glucagon receptor (dual)Partial signal
NCT06066515: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo).
NCT06066528: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo).
TesofensinePhase 3Small moleculeNoradrenaline/dopamine/serotonin reuptakeReliable signal
NCT00394667: After 24 weeks, mean weight loss with diet and placebo was 2.0%, while tesofensine doses produced significantly greater reductions of 4.5%, 9.2% and 10.6% respectively.
UBT251Phase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06939296: Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18).
NCT07011797: Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding.
Visepegenatide (PB-119)
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
VK2735Phase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06828055: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001
ZenagamtidePhase 3PeptideGLP-1/amylin receptor (dual)Weak signal
NCT06064006: Primary outcome, safety (number of treatment-emergent adverse events; no formal efficacy test). Secondary endpoint, estimated mean bodyweight change vs placebo: -24.3% vs -1.1% at week 36 (60 mg), -22.0% vs 1.9% (20 mg, week 36), -16.2% vs 2.3% (5 mg, week 28), -9.7% vs 2.0% (1.25 mg, week 20); p<0.0001 (Parts A-D), p=0.0003 (Part E) (Lancet 2025).
ZovaglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT07020884: Percentage change in body weight from baseline at 24 weeks: -10.6% (80mg monthly), -13.8% (160mg monthly), -12.5% (80mg biweekly), -14.4% (160mg biweekly) vs -2.4% (placebo); p<0.0001.
Efsubaglutide AlfaPhase 2/3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06732960: Efsubaglutide Alfa produced a mean weight reduction of 7.16% (95% CI: -8.08 to -6.24) versus 0.86% with placebo. Overall, 82.5% of Efsubaglutide-treated participants achieved >=5% weight loss (vs. 0% placebo).
ABBV-295Phase 2PeptideAmylin receptorWeak signalFeatured results are safety only in this race
Apitegromab (Isembyld)Phase 2Monoclonal antibodyMyostatin (pro/latent form)Partial signal
NCT06445075: Change from baseline in total Lean Body Mass at 24 weeks: -1.6 kg (-3.4 lbs) with apitegromab+tirzepatide vs -3.5 kg (-7.6 lbs) with placebo+tirzepatide; difference 1.9 kg (4.2 lbs) less lean-mass loss with apitegromab, i.e. 54.9% relative preservation (p=0.001).
ARD-101Phase 2Small moleculeBitter taste receptor (gut)Partial signal
NCT05121441: General-obesity Phase 2 (n=20): ARD-101 produced a 2.51-fold greater reduction in hunger rating (Control of Eating Questionnaire) vs placebo; p=0.015
AT-7687Phase 2PeptideGIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
AZD9550Phase 2PeptideGLP-1/glucagon receptor (dual)Partial signalNo reviewed efficacy summary in this indication
BGM1812Phase 2PeptideAmylin/calcitonin receptor (dual)Weak signal
NCT07224399: Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026)
BI 3034701Phase 2PeptideGLP-1/GIP/NPY2 receptor (triple)Weak signalNo reviewed efficacy summary in this indication
BimagrumabPhase 2Monoclonal antibodyActivin/myostatin type II receptorPartial signal
NCT05616013: Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): 30 mg/kg Bimagrumab -9.25 kilogram (kg) (Standard Error 1.33) | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide -12.73 kilogram (kg) (Standard Error 1.29) | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide -14.31 kilogram (kg) (Standard Error 1.34) | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide -13.86 kilogram (kg) (Standard Error 1.29) | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide -17.79 kilogram (kg) (Standard Error 1.29) vs Placebo + 1.0 mg Semaglutide -9.76 kilogram (kg) (Standard Error 1.25) | Placebo + 2.4 mg Semaglutide -14.24 kilogram (kg) (Standard Error 1.17)
Bremelanotide (Vyleesi)Phase 2PeptideMC4RReliable signal
NCT06565611: BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001.
DapiglutidePhase 2PeptideGLP-1/GLP-2 receptor (dual)Partial signal
NCT05788601: NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. missed
ECC4703Phase 2—Thyroid hormone receptor beta (THRβ)not yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)Phase 2PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EnobosarmPhase 2Small moleculeAndrogen receptor (selective)Partial signal
NCT06282458: Change in total lean body mass at 16 weeks (day 112), enobosarm+semaglutide vs placebo+semaglutide: 71% relative reduction in lean mass loss (p=0.002); 27% greater fat loss vs control
ERX1000Phase 2Small moleculeLeptinWeak signalNo reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Garetosmab (Pasatru)Phase 2Monoclonal antibodyActivin Anot yet gradedNo reviewed efficacy summary in this indication
HM15275Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
HRS-4729Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
LAE102Phase 2Monoclonal antibodyActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
MacupatidePhase 2PeptideGIP receptornot yet gradedNo reviewed efficacy summary in this indication
Metreleptin (Myalept)Phase 2Protein / enzyme therapeuticLeptinPartial signalNo reviewed efficacy summary in this indication
NA-931Phase 2PeptideGLP-1/GIP/glucagon/IGF-1 receptors (quadruple)Partial signal
NCT06564753: Mean body weight reduction from baseline at Week 13: up to 13.8% at the 150 mg daily dose; 11.9% relative to placebo
NimacimabPhase 2Monoclonal antibodyCB1 receptornot yet gradedNo reviewed efficacy summary in this indication
NNC0519-0130Phase 2PeptideGLP-1/GIP receptor (dual)Partial signalNo reviewed efficacy summary in this indication
NNC0662-0419Phase 2PeptideGLP-1 / GIP / Amylin receptorsWeak signalNo reviewed efficacy summary in this indication
Orlistat / Acarbose (EMP16)Phase 2Small moleculeGI lipase + intestinal alpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
ParunoflastPhase 2Small moleculeNLRP3 inflammasome, NLRP3Weak signalFeatured results are safety only in this race
PG-102Phase 2Protein / enzyme therapeuticGLP-1/GLP-2 receptor (dual)Partial signalFeatured results are safety only in this race
Regor GLP-1Phase 2Small moleculeGLP-1 receptorPartial signal
NCT06277934: Safety (this trial's registered primary endpoint): AE-related discontinuation 4%, identical in drug and placebo arms; no treatment-related severe/serious AEs; nausea in 40% and vomiting in 24% of the RGT-075 arm; 1 patient (2%) required dose reduction.
RuvonoflastPhase 2Small moleculeNLRP3 inflammasomePartial signal
NCT07055516: Primary endpoint met: change from baseline in hsCRP up to week 24; effect sizes not yet given (RESOLVE-1, 2026-09-09).
NCT06129409: Phase Ib/IIa trial in 67 obese subjects with elevated CV risk/CRP, 28-day in-clinic dosing. >75% of NT-0796-dosed subjects reached hsCRP ≤2mg/L at day 28 vs <25% of placebo subjects; primary endpoint (hsCRP reduction) met with high statistical significance.
SAL0150
Phase 2(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Taldefgrobep AlfaPhase 2Antibody-derived scaffoldActivin/myostatin type II receptornot yet gradedNo reviewed efficacy summary in this indication
TE-8105Phase 2PeptideGLP-1 receptorWeak signal
NCT06471530: Safety/tolerability (primary): <20% of participants had mild-to-moderate GI symptoms, no severe adverse events. Weight loss: 5 of the B2 cohort participants achieved >5% body weight reduction.
THDBH120Phase 2PeptideGLP-1/GIP receptor (dual)Weak signalFeatured results are safety only in this race
TifeglipronPhase 2Small moleculeGLP-1 receptorPartial signalFeatured results are safety only in this race
TisolagilinePhase 2Small moleculeMAO-Bnot yet gradedNo reviewed efficacy summary in this indication
TrevogrumabPhase 2Monoclonal antibodyMyostatin (GDF8)not yet gradedNo reviewed efficacy summary in this indication
TTP273
Phase 2(overall)
Small moleculeGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
UtreglutidePhase 2PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ZabopegdutidePhase 2PeptideGLP-1/glucagon receptor (dual)Partial signalFeatured results are safety only in this race
ZT006Phase 2PeptideGLP-1 receptorWeak signalNo reviewed efficacy summary in this indication
ARO-ALK7Phase 1/2RNA / oligonucleotideALK7 (Activin receptor-like kinase 7)not yet gradedNo reviewed efficacy summary in this indication
ARO-INHBEPhase 1/2RNA / oligonucleotideINHBE (Inhibin beta E chain / Activin E)not yet gradedNo reviewed efficacy summary in this indication
GUB-UCN2Phase 1/2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
MET-233iPhase 1/2PeptideAmylin receptorWeak signalNo reviewed efficacy summary in this indication
PB-718Phase 1/2PeptideGLP-1/glucagon receptor (dual)Weak signalNo reviewed efficacy summary in this indication
BMF-650Phase 1Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
DehydraTECH-CBD / SemaglutidePhase 1CombinationOral peptide delivery platform, GLP-1 receptorWeak signalFeatured results are safety only in this race
IBI3032Phase 1Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Liraglutide (HUC2-676)Phase 1PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PF-08642534Phase 1UndisclosedGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PF-08656795Phase 1UndisclosedGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (DWRX5003)Phase 1PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
XW014
Phase 1(overall)
Small moleculeGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 110 furthest-along competitors are listed; 25 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

27 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Liraglutide (Saxenda) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1ObesityRecruiting
Est. primary completion 2026-12-13 · NCT07225816 · CT.gov ↗
What to watch
2027 (4)
February 2027 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2027-02-01 · NCT06865365 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4ObesityActive not recruiting
Est. primary completion 2027-04 · NCT07590219 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4ObesityActive not recruiting
Est. primary completion 2027-06 · NCT02944500 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2027-08-31 · NCT07301437 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Phase 4ObesityRecruiting
Est. primary completion 2029-05-30 · NCT06742710 · CT.gov ↗
What to watch

See the full readout calendar ↗